SCLP vs. POLB, FARN, REDX, ETX, FUM, TRX, AREC, 4BB, C4XD, and SAR
Should you be buying Scancell stock or one of its competitors? The main competitors of Scancell include Poolbeg Pharma (POLB), Faron Pharmaceuticals Oy (FARN), Redx Pharma (REDX), e-therapeutics (ETX), Futura Medical (FUM), Tissue Regenix Group (TRX), Arecor Therapeutics (AREC), 4basebio (4BB), C4X Discovery (C4XD), and Sareum (SAR). These companies are all part of the "biotechnology" industry.
Poolbeg Pharma (LON:POLB) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.
Poolbeg Pharma has higher earnings, but lower revenue than Scancell. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Scancell, indicating that it is currently the more affordable of the two stocks.
Poolbeg Pharma has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500. Comparatively, Scancell has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.
6.1% of Poolbeg Pharma shares are owned by institutional investors. Comparatively, 45.6% of Scancell shares are owned by institutional investors. 21.5% of Poolbeg Pharma shares are owned by company insiders. Comparatively, 4.8% of Scancell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Poolbeg Pharma and Poolbeg Pharma both had 1 articles in the media. Poolbeg Pharma's average media sentiment score of 0.67 beat Scancell's score of 0.00 indicating that Scancell is being referred to more favorably in the news media.
Scancell's return on equity of -22.91% beat Poolbeg Pharma's return on equity.
Scancell received 187 more outperform votes than Poolbeg Pharma when rated by MarketBeat users.
Summary
Poolbeg Pharma and Scancell tied by winning 5 of the 10 factors compared between the two stocks.
Get Scancell News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scancell Competitors List
Related Companies and Tools
